At 6.4% CAGR, Europe Parenteral Nutrition Market is Projected to be Worth US$ 3,958.07 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Europe parenteral nutrition market was valued at US$ 2,404.63 million in 2022 and is expected to reach US$ 3,958.07 million by 2030, registering a CAGR of 6.4% from 2022 to 2030. New product developments by companies and innovation in formulations of nutrition products are among the critical factors attributed to the Europe parenteral nutrition market expansion.

Companies operating in the parenteral medical nutrition market constantly focus on new product launches, which help them improve their sales. A few of the noteworthy developments in the parenteral nutrition market are mentioned below:

In 2022, Fresenius Kabi announced the launch of a new website designed to assist medical professionals who work in parenteral nutrition. This website features product details for the Fresenius Kabi line of multi-chamber bags, in addition to information regarding the use of standardized parenteral feeding. The goal is to assist medical professionals in selecting the right product for adult patients requiring parenteral nutrition in various clinical settings.

In 2019, the leading provider of clinical nutrition worldwide, Baxter International Inc., announced the arrival in Europe of Finomel, a parenteral nutrition (PN) ready-to-use triple-chamber bag. Finomel expanded the company's line of premium premixed PN formulations and gave medical professionals more choices to accommodate the varied dietary requirements of adult patients.

Thus, new product development of nutrition is anticipated to create opportunities for the market growth during the forecast period.

On the contrary, mechanical, gastrointestinal, and metabolic complications associated with parenteral feeding systems hampers the growth of Europe parenteral nutrition market.

Based on nutrient type, the Europe parenteral nutrition market is categorized into single dose amino acid solution, parenteral lipid emulsion, carbohydrates, trace elements, and vitamins and minerals. The single dose amino acid solution segment held 33.0% market share in 2022, amassing US$ 793.63 million. It is projected to garner US$ 1,293.81 million by 2030 to register 6.3% CAGR during 2022-2030.

In terms of end user, the Europe parenteral nutrition market is segmented into hospitals, clinics, and others. The hospitals segment held 58.7% share of Europe parenteral nutrition market in 2022, amassing US$ 1,411.32 million. It is projected to garner US$ 2,260.44 million by 2030 to expand at 6.1% CAGR during 2022-2030.

Based on country, the Europe parenteral nutrition market has been categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 26.5% share of Europe parenteral nutrition market in 2022. It was assessed at US$ 637.26 million in 2022 and is likely to hit US$ 1,063.18 million by 2030, exhibiting a CAGR of 6.6% during 2022-2030.

Key players operating in the Europe parenteral nutrition market are ICU Medical Inc, Grifols SA, Pfizer Inc, Otsuka Pharmaceuticals Co Ltd, Baxter International Inc, B Braun SE, Fresenius Kabi AG, Aculife Healthcare Pvt Ltd, and Vifor Pharma Management AG, among others.

• In December 2022, B. Braun SE announced demonstration of its macro and micro compounder, APEX Compounding System and its proprietary TPN Manager Clinical Decision Support Order Entry Software. The demonstration took place from December 5-7, at the Mandalay Bay Convention Center in Las Vegas, during the ASHP Midyear Meeting, in the B. Braun Executive Suite. In order to reduce the chance of precipitation, the TPN Manager program includes Trissel's Ca/P check and enables users to create templates to standardize their order format.
  
  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com